Stockscreener 앱 받기
57.00
4.61%
2.51
시간 외 거래:
57.00
전일 마감가:
$54.49
열려 있는:
$55.7
하루 거래량:
76,445
Relative Volume:
1.77
시가총액:
$351.69M
수익:
-
순이익/손실:
$-7.12M
주가수익비율:
-24.78
EPS:
-2.3
순현금흐름:
$-6.82M
1주 성능:
+26.86%
1개월 성능:
+59.62%
6개월 성능:
+91.60%
1년 성능:
+1,260%
1일 변동 폭
$54.80
$58.94
1주일 범위
$42.51
$58.94
52주 변동 폭
$3.90
$58.94
Monopar Therapeutics Inc Stock (MNPR) Company Profile
명칭
Monopar Therapeutics Inc
전화
(847) 388-0349
주소
1000 SKOKIE BLVD SUITE 350, WILMETTE
MNPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
57.00 | 336.20M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.36 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.24 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.06 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
752.32 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.20 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-09 | 개시 | BTIG Research | Buy |
| 2025-09-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-08-26 | 재개 | H.C. Wainwright | Buy |
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-19 | 재개 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Piper Sandler | Overweight |
| 2024-10-11 | 개시 | Rodman & Renshaw | Buy |
| 2021-01-28 | 개시 | ROTH Capital | Buy |
모두보기
Monopar Therapeutics Inc 주식(MNPR)의 최신 뉴스
Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from BTIG Research - MarketBeat
Promising Long-Term Efficacy and Safety of ALXN1840 Strengthens Buy Rating for Monopar Therapeutics Inc. - TipRanks
Analyzing Monopar Therapeutics Inc. with risk reward ratio chartsMarket Weekly Review & Safe Entry Momentum Tips - newser.com
How to integrate Monopar Therapeutics Inc. into portfolio analysis toolsRecession Risk & Fast Moving Stock Watchlists - newser.com
Historical volatility pattern of Monopar Therapeutics Inc. visualizedTake Profit & Risk Controlled Daily Trade Plans - newser.com
Bull Bear: Will Monopar Therapeutics Inc benefit from green energy policiesMarket Risk Report & Safe Swing Trade Setup Alerts - خودرو بانک
Monopar Therapeutics Presents New Data on ALXN1840 - TipRanks
Bull Run: Is Monopar Therapeutics Inc impacted by rising rates2025 Analyst Calls & Risk Controlled Daily Plans - خودرو بانک
Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout. Here's Why. - Investor's Business Daily
Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout - inkl
BTIG Reiterates Buy Rating on MNPR with $87 Price Target | MNPR Stock News - GuruFocus
Analyzing recovery setups for Monopar Therapeutics Inc. investorsBond Market & Safe Capital Investment Plans - newser.com
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Monopar Therapeutics Inc’s ALXN1840: A Promising Breakthrough in Wilson Disease Treatment Justifying Buy Rating - TipRanks
Can trapped investors hope for a rebound in Monopar Therapeutics Inc.Weekly Risk Report & Weekly Top Gainers Trade List - newser.com
Can volume confirm reversal in Monopar Therapeutics Inc.Weekly Market Outlook & Intraday High Probability Setup Alerts - newser.com
Risk Report: Will Monopar Therapeutics Inc outperform small cap indexesWeekly Investment Recap & AI Driven Price Forecasts - خودرو بانک
Monopar Therapeutics (NASDAQ:MNPR) Now Covered by BTIG Research - MarketBeat
Monopar Therapeutics (MNPR) to Present Promising Wilson Disease Therapy Data - GuruFocus
Full technical analysis of Monopar Therapeutics Inc. stockWeekly Market Outlook & Smart Investment Allocation Tips - newser.com
Is Monopar Therapeutics Inc. stock ready for a breakoutJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Understanding Monopar Therapeutics Inc.’s price movementWall Street Watch & Low Drawdown Investment Ideas - newser.com
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting - The Manila Times
Monopar Therapeutics Presents Promising Long-Term Data on ALXN1840 for Wilson Disease at ANA Annual Meeting - Quiver Quantitative
6 Years of Sustained Brain Function Improvement: Monopar's Wilson Disease Drug Shows Breakthrough Results - Stock Titan
What MACD and RSI say about Monopar Therapeutics Inc.CEO Change & Low Risk High Win Rate Picks - newser.com
What MACD signals say about Monopar Therapeutics Inc.Gap Down & Risk Adjusted Buy and Sell Alerts - Newser
will monopar therapeutics inc. bounce back from current supportMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
Analyzing net buyer seller activity in Monopar Therapeutics Inc.Portfolio Risk Summary & Pattern Based Trade Signal System - Newser
Detecting support and resistance levels for Monopar Therapeutics Inc.Gold Moves & Detailed Earnings Play Alerts - Newser
Evaluating Monopar Therapeutics Inc. with trendline analysisBond Market & Stepwise Entry/Exit Trade Alerts - Newser
Using data models to predict Monopar Therapeutics Inc. stock movementJuly 2025 PostEarnings & Real-Time Volume Analysis - Newser
Momentum divergence signals in Monopar Therapeutics Inc. chartJuly 2025 Review & Free Technical Pattern Based Buy Signals - Newser
Is now a turning point for Monopar Therapeutics Inc.2025 Valuation Update & Long-Term Growth Stock Strategies - Newser
Can machine learning forecast Monopar Therapeutics Inc. recovery2025 Top Gainers & Step-by-Step Trade Execution Guides - Newser
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Monopar Therapeutics Inc (MNPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Monopar Therapeutics Inc 주식 (MNPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
| Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
0.77%
1.53%
자본화:
|
볼륨(24시간):